31 Related party disclosures

The parent company of Carl Zeiss Meditec AG is Carl Zeiss AG, which is controlled by the Carl Zeiss Foundation (Carl-Zeiss-Stiftung). Related parties within the meaning of IAS 24 Related party disclosures include the Carl-Zeiss-Stiftung, Heidenheim an der Brenz and Jena, Carl Zeiss AG, Oberkochen, and its subsidiaries excluding the Carl Zeiss Meditec Group (the “ZEISS Group”), Schott AG, Mainz, including its subsidiaries (the “Schott Group”), associates and joint ventures as well as the members of the Management Board and Supervisory Board (key management personnel) of Carl Zeiss Meditec AG and their immediate family members. Further information can be found in Note 35 “Other mandatory disclosures pursuant to Section 315e HGB”.

The Carl Zeiss Meditec Group sells some of its products to the sales companies of the ZEISS Group. For the purposes of furnishing the Company with short-term funds and investing surplus liquidity, Carl Zeiss Meditec mainly cooperates with the group cash management system of Carl Zeiss Financial Services GmbH, Oberkochen. Loans granted and monies invested within the scope of this business relationship are carried under liabilities to or receivables from treasury, and are usually due or available daily.

In addition to financial services, the Company procures various services from the ZEISS Group, including Carl Zeiss AG. These include, among others, research and development services, personnel and administrative activities, the leasing of administrative and production buildings, as well as the licensed use of the “ZEISS” brand, as well as logistics, distribution and IT services provided on the basis of contractual agreements. In addition, some preliminary products are procured from companies of the ZEISS Group and the Schott Group. Carl Zeiss Meditec AG incurs no disadvantages from business transactions with related parties compared to similar business transactions with independent business partners.

The following tables show related party transactions and outstanding balances:

The financial income and expenses presented above mainly include effects from the recognition and valuation of forward exchange contracts.

The amounts presented above include treasury receivables of €128,976k (prior year: €116,660k) and treasury payables of €32,784k (prior year: €64,039k), mainly to Carl Zeiss Financial Services GmbH. They also include loans to associated companies amounting to €6,656k (prior year: €6,240k).

In accordance with the expected loss model of IFRS 9, impairment losses were also recognized on balances due from related parties for a technically expected loss based on rating information. As of 30 September 2025, these impairment losses totaled €3,852k (prior year: €3,753k), of which €3,422k (prior year: €3,209k) is attributable to loans. This had an effect on earnings of €-149k (prior year: €-122k) in the fiscal year under review. A deterioration in creditworthiness or a default was not identified in any case. For more details on the impairment losses recognized, please refer to Note 26 “Financial instruments and risk management”.

The loans granted by the ZEISS Group and funds invested with said company are subject to variable interest at normal market conditions.

There were no transactions with the Carl Zeiss Foundation in the past fiscal year; there were no outstanding items at the end of the reporting period.

The remuneration paid to the Group’s management in key positions (Management Board and Supervisory Board) comprises the following:

In addition to their fixed remuneration, members of management in key positions receive a short-term and a long-term variable remuneration component. This variable remuneration component is based on key earnings figures. Pension entitlements are also earned. Furthermore, a severance payment was made to Dr. Markus Weber in this fiscal year.